HNGE vs HIMS

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 50. 6% for Hinge Health, Inc. (HNGE). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 52. 6x trailing P/E, making it the more compelling value choice. Analysts rate Hinge Health, Inc. (HNGE) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +107. 9%, compared to +74. 0% for Hinge Health, Inc. (HNGE). Over 10 years, the gap is even starker: HIMS returned +173. 7% versus HNGE's +74. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hinge Health, Inc.

(HNGE) is the lower-risk stock at 1. 32β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 87% more volatile than HNGE relative to the S&P 500. On balance sheet safety, Hinge Health, Inc. (HNGE) carries a lower debt/equity ratio of 2% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus 50. 6% for Hinge Health, Inc. (HNGE). On earnings-per-share growth, the picture is similar: Hims & Hers Health, Inc. grew EPS -3. 8% year-over-year, compared to -33. 6% for Hinge Health, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -89. 9% for Hinge Health, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 4. 5% versus -92. 9% for HNGE. At the gross margin level — before operating expenses — HNGE leads at 79. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for HNGE: 13.

5% to $74. 18.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hinge Health, Inc.

(HNGE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HNGE: +74. 0%, HIMS: +173. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.